Introduction: Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several malignancies both in the adjuvant and metastatic setting. Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities.
We describe a case of pulmonary veno-occlusive disease (PVOD) related to gemcitabine.
Case presentation: The patient was an 83-year-old man with a metastatic pancreatic cancer who was treated by gemcitabine as first-line therapy. He was in good health and received no other chemotherapy.
A dose of 1000 mg/m2 of gemcitabine was administered over a 30-minute intravenous infu-sion on days 1, 8, and 15 of a 28-day cycle. After a period of 6 months, a complete response was observed.
Nevertheless, the patient developed a severe dyspnea, with arterial hypoxemia and very low lung diffusion for carbon monoxide. A CT scan showed diffuse ground glass opacities with septal lines, bilateral pleural effusion, and lymph node enlargement.
On echocardiography, there was a suspicion of pulmonary hypertension with elevated systolic pulmonary artery pressure and normal left ventricular pressures. Right heart catheterization confirmed pulmonary hypertension and normal pulmonary artery occlusion pressure.
Diagnosis of PVOD was made, and a gemcitabine-induced toxicity was suspected. A symptomatic treatment was started.
At last follow-up, patient was in functional class I with near-normal of CT scan, arterial blood gases, and echocardiography. A gemcitabine-induced PVOD is the more likely diagnosis.
Keywords: gemcitabine, pancreatic cancer, pulmonary toxicities, veno occlusive disease
Citation: Turco et al. Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease. Clinical Medicine Insights: Oncology 2015:9 75–79 doi: 10.4137/CMO.S26537.
Received: March 24, 2015. Resubmitted: May 04, 2015. Publication Date: May 05, 2015.
Academic Editor: William C S Cho, Editor in Chief
Type: Case Report
Funding: Authors disclose no funding sources.
Competing Interests: Authors disclose no potential conflicts of interest.
Correspondence: [email protected]
Copyright: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).
Published by Libertas Academica. Learn more about this journal.